# Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts

> **NCT02967666** · PHASE1 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 30 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **RADIATION:** FDG ligand
- **RADIATION:** DOTANOC ligand

## Key facts

- **NCT ID:** NCT02967666
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2017-05
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02967666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02967666, "Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02967666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*